Compare LXFR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | AUTL |
|---|---|---|
| Founded | 1898 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.7M | 428.5M |
| IPO Year | 2002 | 2025 |
| Metric | LXFR | AUTL |
|---|---|---|
| Price | $17.11 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 145.0K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $384,600,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | $5.01 | $53.96 |
| P/E Ratio | $131.23 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $11.19 | $1.18 |
| 52 Week High | $19.45 | $2.70 |
| Indicator | LXFR | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 42.06 |
| Support Level | $16.68 | $1.38 |
| Resistance Level | $19.45 | $1.52 |
| Average True Range (ATR) | 0.63 | 0.10 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 23.86 | 3.77 |
Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.